Gavi facts and figures

in page functions
[French]

Statistics measuring Gavi, the Vaccine Alliance's impact on global immunisation

Every year, academics, journalists, teachers and students ask for statistics detailing Gavi's results since the Vaccine Alliance was established in 2000. Sourcing the Gavi Secretariat and members of the Vaccine Alliance, including WHO, UNICEF and civil society organisations, these key facts and figures list Gavi's achievements to date as well as demonstrating the Vaccine Alliance's catalytic role within global immunisation.

US$ 80-100 billion

Investing in Gavi’s 2016-2020 strategy has the potential to deliver US$ 80-100 billion in costs averted related to illness, such as productivity loss due to death/disability, treatment costs, caretaker productivity loss and transport costs.

Source: Stack M et al. Estimated economic benefits during Decade of Vaccines, Health Affairs 2011

62 million

In 2016 alone, 62 million children were immunised with Gavi-supported vaccines. This equates to more than 185 million points of contact between these children and the primary health system and provides a robust platform for other health interventions.

Source: WHO/UNICEF 2017

>200

Gavi supported over 200 vaccine introductions and campaigns in the 2011–2015 period – four times as many as in the previous five years.

Source: Gavi

>60

The Vaccine Alliance has helped to strengthen health systems and immunisation services in more than 60 countries.

Source: Gavi

>1 million

Since the first human papillomavirus (HPV) vaccine demonstration programme in Kenya in 2013, over 1 million girls have been immunised with Gavi support. By the end of 2016, Gavi was supporting national HPV vaccine programmes in Honduras, Rwanda and Uganda.

Source: Gavi

40 million

In September 2014, Nepal became the first country to introduce inactivated polio vaccine (IPV) with Gavi support. By the end of 2016, 54 countries had introduced the vaccine with our support, collectively immunising more than 40 million children.

Source: Gavi

41 million

Since 2007, countries have immunised 41 million children with a second dose of measles or measles-rubella vaccine with Gavi support. Gavi-funded campaigns with these two vaccines have helped vaccinate another 328 million children in countries at high risk of outbreaks.

Source: WHO/UNICEF and Gavi, 2017

>100 million

Since 2011, Gavi-supported yellow fever campaigns have protected over 98 million people in 14 countries. We have also helped 17 countries introduce yellow fever vaccine through routine immunisation, immunising more than 100 million children.

Source: Gavi

>2 million

Since its creation in 2013, the global oral cholera vaccine stockpile has been used to vaccinate more than 2 million people. In 2016, eight countries – the Democratic Republic of the Congo, Haiti, Mozambique, Malawi, Niger, Somalia, South Sudan and Zambia – accessed the stockpile.

Source: Gavi

US$ 1 = US$ 18

A study in Health Affairs covering 73 Gavi-supported countries over the 2011–2020 period shows that, for every US$ 1 spent on immunisation, US$ 18 are saved in healthcare costs, lost wages and lost productivity due to illness. If we take into account the broader benefits of people living longer, healthier lives, the return on investment rises to US$ 48 per US$ 1 spent.

Source: Ozawa S, Clark S, Portnoy A et al. Return on investment from childhood immunizations in low- and middle-income countries, 2011-20, Health Affairs 2016

>268 million

By the end of 2016, 19 countries in the African meningitis belt had immunised over 268 million people against meningitis A with Gavi support.

Source: WHO/UNICEF and Gavi 2017

7%

Only 7% of children in Gavi-supported countries have access to all 11 vaccines recommended by WHO for infants in all countries.

Source: WHO/UNICEF, UNDP 2017

Every 2 minutes

One woman dies from cervical cancer every two minutes – or 266,000 a year – over 85% in the developing world. If current trends hold, and without changes in prevention and control, cervical cancer deaths could eventually outpace maternal deaths. HPV vaccines can prevent up to 90% of all cervical cancer cases.

Source: WHO

>9 million

Since its inception in 2000, Gavi has helped developing countries to prevent more than 9 million future deaths through its support to 10 vaccines: pentavalent, pneumococcal, rotavirus, yellow fever, meningitis A, Japanese encephalitis, human papillomavirus (HPV), measles second dose, measles-rubella and rubella.

Source: WHO/UNICEF and Gavi, 2017

Close to 640 million

Since 2000, Gavi support has contributed to the immunisation of close to 640 million children.

Source: WHO/UNICEF 2017

>109 million

By the end of 2016, 57 countries had immunised more than 109 million children against pneumococcal disease with support from the Vaccine Alliance.

Source: WHO/UNICEF 2017

277 million

Gavi support helped countries to immunise 277 million children between 2011 and 2015.

Source: WHO/UNICEF 2016

28%

Pneumonia and diarrhoea account for 28% of deaths in under-fives in Gavi-supported countries.

Source: MCEE-WHO 2016

20 by 2020

Gavi continues to help countries to build sustainable immunisation programmes. Nine countries have already started to fully self-finance all their vaccines introduced with Gavi funding. By the end of 2020, a total of 20 countries are expected to have transitioned out of our support.

Source: Gavi

>54 million

Our support has contributed to immunising over 54 million children against rotavirus diarrhoea. By the end of 2016, 40 countries had introduced the vaccine with support from the Vaccine Alliance.

Source: WHO/UNICEF 2017

>4 million

The Vaccine Alliance’s support for vaccines contributed to averting more than 4 million future deaths between 2011 and 2015.

Source: Gavi, the Vaccine Alliance/Bill & Melinda Gates Foundation 2016

48%

The weighted average price of pentavalent vaccine per dose dropped from US$ 2.98 in 2010 to US$ 1.55 in 2016, and is expected to decrease further to US$ 0.79 by 2019.

Source: Gavi

1.5 million

In 2012, approximately 6.6 million children died before the age of five. WHO estimates that 1.5 million of these deaths are due to vaccine-preventable diseases.

Source: WHO

5 -> 16

From 5 to 16 vaccine manufacturers supplying Gavi – more than half based in Africa, Asia and Latin America.

2001: 5 vaccine manufacturers producing prequalified, appropriate Gavi vaccines – 1 based in Africa;
2016: 16 vaccine manufacturers producing prequalified, appropriate Gavi vaccines – 9 based in Africa, Asia and Latin America.

Source: Gavi 2017

19.5 million

19.5 million infants remain underimmunised with three doses of DTP in the world each year. One in five of all children in Gavi-supported countries miss out on a full course of this basic package of vaccines.

Source: WHO/UNICEF 2017

close icon

modal window here